Key Drivers
- High margins
- Strong cashflow
- Low leverage
AIAI Summary
Cellebrite's shift to cloud‑native, AI‑led SaaS is materially reweighting its value from one‑off device sales to high‑margin, recurring ARR—so investors should prioritize ARR growth, retention, and cloud/AI adoption metrics over headline revenue. The key risk is execution: failure to convert federal and legacy customers to cloud or to integrate acquisitions (and navigate regulatory/AI policy hurdles) would quickly compress its premium multiple.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Strong cashflow
- •Low leverage
CLBT demonstrates high profitability and strong free-cash-generation with conservative leverage but elevated valuation and material intangible/deferred-revenue and investing risks.
Price Behavior
Key Price Behavior Insights:
- •Modest uptrend
- •Momentum weakening
- •Elevated volatility
Over the last month CLBT shows a modest single‑digit uptrend to 2026-03-20 but with weakening momentum since the early‑March peak and elevated intra‑period volatility that raises short‑term downside risk.
Sharp day-to-day swings and at least one steep intra-period decline indicating heightened short-term risk
Sentiment & News
Key News Insights:
- •AI product launches
- •UAV forensics
- •Institutional stake increase
Cellebrite accelerated product and capability expansion—launching AI tools (Genesis, Guardian Investigate), completing a UAV-forensics acquisition, updating its 20‑F and drawing increased institutional interest—signaling renewed growth and investor engagement.
These developments should strengthen CLBT's product-led revenue pipeline and investor sentiment, supporting its valuation if adoption and integration proceed smoothly
Similar Companies in Technology
Other companies in the same sector with AI ratings